MEDIAN Technologies to Participate in the 2013 ASCO Annual Conference
MEDIAN will demonstrate its Lesion Management Solutions (LMS) and discuss the results of its abstract at Booth #3097, Hall B
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced its participation in the 2013 ASCO annual conference, to be held next May 31 – June 4, in Chicago, IL, USA (exhibition dates: June 1-3).
During ASCO, the world’s premier oncology conference, representatives from MEDIAN will be present at Booth #3097, Hall B to give demonstrations of their Lesion Management Solutions software and to discuss their abstract, ‘Determination of thresholds for the assessment of response to therapy relying on volume-based tumor burden in pulmonary CT images’. Today, Response Evaluation Criteria In Solid Tumors (RECIST) provide indications on tumor burden, based on the measurement of the Longest Axial Diameter of malignant tumors. RECIST enables the assessment of response to therapy of cancer patients enrolled in clinical trials. However, a growing medical community now believes that RECIST is limited because it relies on an approximate estimate of the tumor burden. This limitation could be overcome by using tumor volume as another imaging biomarker, reflecting more accurate tumor burden. The study performed by MEDIAN in collaboration with clinical sites based in France and Germany, deals with the utilization of tumor volume as an indicator of response to therapy and more specifically, with the applicable threshold values enabling physicians to diagnose whether or not the patient responds to therapy. The study is based on published data from the Quantitative Imaging Biomarker Alliance (QIBA) about the inter-reader measurement variability and on clinical data from a retrospective study on pulmonary cancer patients (NSCLC) followed with CT imaging.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”